Old drugs get new rebate breaks—at Medicare's expense
H.R. 2542 — Old Drugs, New Cures Act · Filed by Donald Davis (D-NC) · 1 cosponsor · Introduced Apr 1, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a fast-track designation process for old drugs being studied for new medical uses. If a drug has been on the market for at least 10 years and a manufacturer is testing it for a new indication that addresses an unmet medical need affecting a large share of Medicare/Medicaid beneficiaries, the drug can be designated a 'priority research drug.' Once designated, these drugs are excluded from being treated as 'line extensions' of the original drug for purposes of calculating manufacturer rebates under Medicare and Medicaid, potentially lowering the rebates owed and increasing the drug's profitability.
Why we flagged it
The bill's operative mechanism is a narrow financial exemption for a specific class of drugs (old drugs being studied for new uses) from rebate calculations. The public-health framing (incentivizing research into unmet medical needs) masks a direct reduction in the rebates manufacturers must pay to government health programs.
What the text implies
- The 'high prevalence' threshold (33% of claims from federal programs) is low enough that many common chronic diseases in elderly/low-income populations would qualify, potentially opening the exemption to a broad class of drugs.
- The bill does not require the manufacturer to demonstrate that the rebate reduction is necessary to fund the research; it is a blanket exemption tied only to the drug's age and the indication's prevalence.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers with drugs approved 10+ years ago; companies conducting clinical trials on old drugs for new indications